Literature DB >> 3770015

Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone.

U Täuber, K Schröder, B Düsterberg, H Matthes.   

Abstract

The plasma levels of testosterone (T) were measured after oral administration of 25 mg T and 40 mg testosterone-undecanoate (TU) in a group of young women by a specific radioimmunoassay. Plasma levels were compared to those after intravenous administration of 1.5 micrograms testosterone/kg to another group of young women for determination of absolute bioavailability. Due to the high metabolic clearance rate of 24.5 ml/min/kg absolute systemic availability of free testosterone was calculated to 3.56 +/- 2.45%. Oral administration of testosterone undecanoate leads only to an absolute testosterone bioavailability of 6.83 +/- 3.32%.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3770015     DOI: 10.1007/BF03189840

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  11 in total

1.  Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men.

Authors:  T Schürmeyer; E J Wickings; C W Freischem; E Nieschlag
Journal:  Acta Endocrinol (Copenh)       Date:  1983-03

2.  Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men.

Authors:  T Schürmeyer; E Nieschlag
Journal:  Int J Androl       Date:  1984-06

3.  Oral testosterone, a reappraisal.

Authors:  P R Daggett; M J Wheeler; J D Nabarro
Journal:  Horm Res       Date:  1978

4.  Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone.

Authors:  R Horton; J F Tait
Journal:  J Clin Invest       Date:  1966-03       Impact factor: 14.808

5.  The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen.

Authors:  A Coert; J Geelen; J de Visser; J van der Vies
Journal:  Acta Endocrinol (Copenh)       Date:  1975-08

6.  Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate.

Authors:  E Nieschlag; J Mauss; A Coert; P Kićović
Journal:  Acta Endocrinol (Copenh)       Date:  1975-06

7.  Which testosterone replacement therapy?

Authors:  J A Cantrill; P Dewis; D M Large; M Newman; D C Anderson
Journal:  Clin Endocrinol (Oxf)       Date:  1984-08       Impact factor: 3.478

8.  Mean plasma concentration, metabolic clearance and basal plasma production rates of testosterone in normal young men and women using a constant infusion procedure: effect of time of day and plasma concentration on the metabolic clearance rate of testosterone.

Authors:  A L Southren; G G Gordon; S Tochimoto; G Pinzon; D R Lane; W Stypulkowski
Journal:  J Clin Endocrinol Metab       Date:  1967-05       Impact factor: 5.958

9.  Influence of sex, testicular development and liver function on the bioavailability of oral testosterone.

Authors:  E Nieschlag; H J Cüppers; E J Wickings
Journal:  Eur J Clin Invest       Date:  1977-04       Impact factor: 4.686

10.  Bioavailability of oral testosterone in males.

Authors:  H Frey; A Aakvaag; D Saanum; J Falch
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

View more
  17 in total

1.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

Review 2.  Lipid-based drug carriers for prodrugs to enhance drug delivery.

Authors:  Jennica L Zaro
Journal:  AAPS J       Date:  2014-10-01       Impact factor: 4.009

Review 3.  Transdermal patches: history, development and pharmacology.

Authors:  Michael N Pastore; Yogeshvar N Kalia; Michael Horstmann; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2015-03-18       Impact factor: 8.739

4.  Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone.

Authors:  L Tax
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jul-Sep       Impact factor: 2.441

5.  Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation.

Authors:  Anthony Y Yin; Michelle Htun; Ronald S Swerdloff; Maruja Diaz-Arjonilla; Robert E Dudley; Sandra Faulkner; Rachelle Bross; Andrew Leung; Sima Baravarian; Laura Hull; James A Longstreth; Steven Kulback; Gregory Flippo; Christina Wang
Journal:  J Androl       Date:  2011-04-07

Review 6.  A new oral testosterone undecanoate formulation.

Authors:  Frank-Michael Köhn; Wolf-Bernhard Schill
Journal:  World J Urol       Date:  2003-10-25       Impact factor: 4.226

7.  Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism.

Authors:  Haeyoung Zhang; Abdul Basit; Diana Busch; King Yabut; Deepak Kumar Bhatt; Marek Drozdzik; Marek Ostrowski; Albert Li; Carol Collins; Stefan Oswald; Bhagwat Prasad
Journal:  Biochem Pharmacol       Date:  2018-08-04       Impact factor: 5.858

8.  Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Bradley D Anawalt; Richard A Anderson; William J Bremner; Joerg Elliesen; Yi-Qun Gu; Wendy M Kersemaekers; Robert I McLachlan; M Cristina Meriggiola; Eberhard Nieschlag; Regine Sitruk-Ware; Kirsten Vogelsong; Xing-Hai Wang; Frederick C W Wu; Michael Zitzmann; David J Handelsman; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2008-02-26       Impact factor: 5.958

9.  Comparison of the single dose pharmacokinetics, pharmacodynamics, and safety of two novel oral formulations of dimethandrolone undecanoate (DMAU): a potential oral, male contraceptive.

Authors:  R Ayoub; S T Page; R S Swerdloff; P Y Liu; J K Amory; A Leung; L Hull; D Blithe; A Christy; J H Chao; W J Bremner; C Wang
Journal:  Andrology       Date:  2016-12-01       Impact factor: 4.456

10.  Acceptability of oral dimethandrolone undecanoate in a 28-day placebo-controlled trial of a hormonal male contraceptive prototype.

Authors:  Brian T Nguyen; Maritza T Farrant; Bradley D Anawalt; Fiona Yuen; Arthi Thirumalai; John K Amory; Ronald S Swerdloff; William J Bremner; Peter Y Liu; Diana L Blithe; Stephanie T Page; Christina Wang
Journal:  Contraception       Date:  2020-04-13       Impact factor: 3.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.